IN2012DN01325A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01325A
IN2012DN01325A IN1325DEN2012A IN2012DN01325A IN 2012DN01325 A IN2012DN01325 A IN 2012DN01325A IN 1325DEN2012 A IN1325DEN2012 A IN 1325DEN2012A IN 2012DN01325 A IN2012DN01325 A IN 2012DN01325A
Authority
IN
India
Prior art keywords
alkyl
independently
pi3k
heteroaryl
inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen Joseph Shuttleworth
Alexander Richard Liam Cecil
Thomas James Hill
Franck Alexandre Silva
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0914594A external-priority patent/GB0914594D0/en
Priority claimed from GBGB1005584.6A external-priority patent/GB201005584D0/en
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of IN2012DN01325A publication Critical patent/IN2012DN01325A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN1325DEN2012 2009-08-20 2010-08-19 IN2012DN01325A (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0914594A GB0914594D0 (en) 2009-08-20 2009-08-20 Compounds
GBGB1005584.6A GB201005584D0 (en) 2010-04-01 2010-04-01 Compounds
PCT/GB2010/051370 WO2011021038A1 (en) 2009-08-20 2010-08-19 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN01325A true IN2012DN01325A (xx) 2015-06-05

Family

ID=42756474

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1325DEN2012 IN2012DN01325A (xx) 2009-08-20 2010-08-19

Country Status (15)

Country Link
US (4) US9200007B2 (xx)
EP (1) EP2467387B1 (xx)
JP (1) JP5746172B2 (xx)
CN (1) CN102498115B (xx)
AU (1) AU2010286168B2 (xx)
BR (1) BR112012003955A2 (xx)
CA (1) CA2771594C (xx)
ES (1) ES2534326T3 (xx)
IL (1) IL217903A (xx)
IN (1) IN2012DN01325A (xx)
MX (1) MX2012002059A (xx)
NZ (1) NZ597983A (xx)
PL (1) PL2467387T3 (xx)
WO (1) WO2011021038A1 (xx)
ZA (1) ZA201200910B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010286168B2 (en) 2009-08-20 2014-05-15 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
AU2015268776B2 (en) * 2010-12-16 2017-04-13 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
TW201500358A (zh) * 2010-12-16 2015-01-01 Hoffmann La Roche 三環ｐｉ３ｋ抑制劑化合物及其使用方法
KR102038462B1 (ko) 2011-12-15 2019-10-31 노파르티스 아게 Pi3k의 활성 또는 기능의 억제제의 용도
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
EP2897959B1 (en) 2012-09-20 2017-12-20 UDC Ireland Limited Azadibenzofurans for electronic applications
US9676765B2 (en) 2012-11-07 2017-06-13 Karus Therapeutics Limited Histone deacetylase inhibitors and their use in therapy
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
AR095443A1 (es) * 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
LT2994465T (lt) 2013-05-10 2018-10-10 Karus Therapeutics Limited Nauji histono deacetilazės inhibitoriai
US9814037B2 (en) * 2013-06-28 2017-11-07 Intel Corporation Method for efficient channel estimation and beamforming in FDD system by exploiting uplink-downlink correspondence
CN104557955B (zh) * 2013-10-23 2017-05-03 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
HRP20220227T1 (hr) * 2015-12-16 2022-04-29 Genentech, Inc. Postupak priprave tricikličnih spojeva inhibitora p13k i postupci upotrebe navedenih spojeva u liječenju raka
KR102474326B1 (ko) 2016-06-22 2022-12-05 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3558309B1 (en) 2016-11-07 2023-07-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
MA46899A (fr) 2016-11-07 2021-04-14 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
JP7098167B2 (ja) 2016-11-07 2022-07-11 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
CN111406058A (zh) 2017-12-05 2020-07-10 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
MX2020007392A (es) 2018-01-10 2020-10-14 Recurium Ip Holdings Llc Compuestos de benzamida.
WO2022169882A1 (en) 2021-02-03 2022-08-11 Verge Analytics, Inc. Methods and treatment of viral infection caused by sars-cov-2
WO2023020604A1 (zh) * 2021-08-20 2023-02-23 南京大美生物制药有限公司 一种五元含氮杂环并杂芳基类衍生物及其用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN1186324C (zh) * 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
CA2414468A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2005217320B2 (en) 2004-02-26 2011-07-21 Aska Pharmaceuticals Co., Ltd. Pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
ATE540948T1 (de) 2005-05-20 2012-01-15 Vertex Pharma Pyrrolopyridine als proteinkinasehemmer
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
KR20090021155A (ko) 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
JP5291616B2 (ja) * 2006-04-26 2013-09-18 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ抑制剤化合物およびその使用方法
ATE510840T1 (de) 2006-06-26 2011-06-15 Ucb Pharma Sa Kondensierte thiazol-derivate als kinasehemmer
KR20090087027A (ko) 2006-11-13 2009-08-14 일라이 릴리 앤드 캄파니 염증 질환 및 암의 치료를 위한 티에노피리미디논
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
WO2008121257A1 (en) 2007-03-28 2008-10-09 Merck & Co., Inc. Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
JP5581219B2 (ja) * 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
US20110201608A1 (en) 2008-08-05 2011-08-18 Boehringer Ingelheim International Gmbh Substituted naphthyridines and use thereof as medicines
EP2344490A2 (en) 2008-10-03 2011-07-20 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines active on pi3k
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2011012883A1 (en) 2009-07-29 2011-02-03 Karus Therapeutics Limited Benzo [e] [1, 3 ] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
AU2010286168B2 (en) 2009-08-20 2014-05-15 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
ME02887B (me) 2011-07-27 2018-04-20 Astrazeneca Ab 2-(2,4,5-supstituisani-anilino) pirimidinski derivati kao egfr modulatori korisni za tretman raka
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
EP3181564B1 (en) 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
LT2994465T (lt) 2013-05-10 2018-10-10 Karus Therapeutics Limited Nauji histono deacetilazės inhibitoriai
MX2015016277A (es) 2013-05-30 2016-08-11 Infinity Pharmaceuticals Inc Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa.
EP3052494B1 (en) 2013-06-28 2018-12-26 H. Hoffnabb-La Roche Ag Azaindazole compounds as inhibitors of t790m containing egfr mutants
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
MX2012002059A (es) 2012-04-19
BR112012003955A2 (pt) 2017-09-26
EP2467387B1 (en) 2015-01-07
US10501478B2 (en) 2019-12-10
US9200007B2 (en) 2015-12-01
CN102498115B (zh) 2016-12-07
CA2771594C (en) 2018-05-01
PL2467387T3 (pl) 2015-08-31
IL217903A (en) 2017-08-31
US20180009826A1 (en) 2018-01-11
US20120178737A1 (en) 2012-07-12
US9938290B2 (en) 2018-04-10
ZA201200910B (en) 2013-05-29
AU2010286168A1 (en) 2012-03-08
ES2534326T3 (es) 2015-04-21
EP2467387A1 (en) 2012-06-27
CN102498115A (zh) 2012-06-13
JP5746172B2 (ja) 2015-07-08
US20190040079A1 (en) 2019-02-07
CA2771594A1 (en) 2011-02-24
NZ597983A (en) 2014-05-30
JP2013502404A (ja) 2013-01-24
US20160108057A1 (en) 2016-04-21
WO2011021038A1 (en) 2011-02-24
AU2010286168B2 (en) 2014-05-15
IL217903A0 (en) 2012-03-29
US9580442B2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
IN2012DN01325A (xx)
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
GEP201706728B (en) Noxious organism control agent
MD4582C1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
TW201204363A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
TN2011000400A1 (en) Inhibitors of beta-secretase
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
MY155517A (en) Heterocyclic derivatives
EA201391098A1 (ru) C-28-амины c-3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
MD20140023A2 (ro) Derivaţi de pirolpirimidină şi purină
JO3465B1 (ar) مركب متغاير الحلقه واستخدامه
MX2010006421A (es) Compuestos organicos.
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MX2015008971A (es) Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor.
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX347616B (es) Inhibidores de csf-1r para el tratamiento de tumores de cerebro.
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
HK1138262A1 (en) Novel phosphodiesterase inhibitors
IN2014DN07509A (xx)
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
NZ605558A (en) Benzamide derivatives and their use as hsp90 inhibitors
PH12015502429A1 (en) Dicarboxylic acid compound